Trial Profile
1454GCC: Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- 26 Jul 2018 Status changed from active, no longer recruiting to discontinued due to the inclusion of an IMid in combination with pembrolizumab, study sponsor terminated the study.
- 01 May 2017 Results published in the Blood
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.